Product Description: Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential application in acute optic neuritis and relapse multiple sclerosis[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Cadavid D, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 Mar;16(3):189-199./[2]Cadavid D, et al. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019 Sep;18(9):845-856.
CAS Number: 1422268-07-2
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Others